We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

Morcellator Cancer Reports Drop, Essure Reports Rise

Drugwatch, June 20, 2017:Reports of cancer that was spread by power morcellators have decreased, while injuries from Essure sterilization (permanent birth control) devices have increased. We join other experts who are concerned about FDA’s reporting system and emphasize our support of the Medical Device Safety Act, which would improve the safety of medical devices

It’s Not Safe in Soap, But You Touch It Everyday

Marketwatch, June 21 2017: Some soaps contain triclosan and other chemicals that can disrupt hormones and be harmful to health. Experts say these ingredients offer little benefit and pose risks. The FDA has banned certain antibacterial agents in soaps, but these chemicals are still found in other products, raising concerns about daily exposure.

If Drug Companies Are ‘Getting Away With Murder,’ Trump May Grant Them a Pardon

STAT, June 19, 2017. Trump’s team is reportedly considering moves that would do little to address the problem — and would instead please the pharmaceutical industry.

Why Are So Many American Women Having Mastectomies?

Our Bodies Ourselves, June 16, 2017. Breast cancer experts believe that many women undergoing mastectomies do not need them and are getting them out of fear, not because of the actual risks.

Will a New FDA User Fee Discourage Medical Device Innovation?

Bloomberg June 12, 2017: The NCHR is warning that a new FDA user fee could make the de novo pathway more appealing by speeding up device reviews, but at the cost of safety. NCHR says this fast-track process often skips clinical trials and lacks solid scientific proof, putting patients at risk.